Document is current
Any future updates will be listed below
-
Authors
Rethorst, Chad D. https://orcid.org/0000-0002-8168-2829
Carmody, Thomas J.
Argenbright, Keith E.
Vazquez, Louis
DeLuca, Thomas
Mayes, Taryn L.
Hamann, Heidi A.
Trivedi, Madhukar H.
-
Funding
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (PP160121)
- License Information
-
More Information
Article History
Received: 28 October 2022
Accepted: 4 September 2024
First Online: 21 September 2024
Declarations
:
: Within the past 36 months, MHT has provided consulting services to ACADIA Pharmaceuticals, Allergan, Alkermes Inc., Alto Neuroscience Inc, Applied Clinical Intelligence, LLC, Axsome Therapeutics, Biogen MA Inc, Boegringer Ingelheim, Cerebral Inc., Circular Genomics Inc., Compass Pathfinder Limited, GH Research, GreenLight VitalSign6 Inc, Heading Health, Health Care Global Village, Janssen Pharmaceutical, Jazz Pharmaceutical, Legion Health, Lundbeck Research USA, Merck Sharp & Dohme Corp., Mind Medicine Inc., Myriad Neuroscience, Naki Health Ltd, Navitor, Neurocrine Biosciences Inc., Noema Pharma AG, Orexo US Inc., Otsuka America Pharmaceutical Inc, Perception Neuroscience Holdings, Pharmerit International, Policy Analysis Inc., Praxis Precision Medicines Inc, Rexahn Pharmaceuticals, Inc., SAGE Therapeutics, Signant Health, Sparian Biosciences, Titan Pharmaceuticals, Takeda Pharmaceuticals Inc, WebMD. He has received grant/research funding from NIMH, NIDA, NCATS, American Foundation for Suicide Prevention, Patient-Centered Outcomes Research Institute (PCORI), and Blue Cross Blue Shield of Texas. Additionally, he has received editorial compensation from Engage Health Media, and Oxford University Press. All other authors have no competing interests to report.
